The Emerging Landscape of GLP-1 RA Therapies
The founder and CEO of Phesi, Gen Li, PhD, addresses the need for streamlining clinical trial data as GLP-1 RA therapies are used to treat multiple diseases.
GLP-1 RA therapies are being used in clinical trials to treat overlapping conditions, including some unrelated to obesity, with over 100 diseases currently being studied.
The rapid growth of GLP-1 RA therapies creates an incentive for efficient and easily accessible clinical trial data.
- Phesi provides artificial intelligence–driven insights to optimize clinical trial efficacy.
- Phesi data aids sponsors and researchers in establishing control cohorts.
Author's summary: GLP-1 RA therapies are expanding across multiple conditions.